Detail of "163252-36-6"

Reference

Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B

All Rights Reserved. Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. Yuan, He-Jun; Lee, William M. (Division of Digestive and Liver Diseases, L5-210, University of Texas Southwestern Medical School, Dallas, TX 75390-8887, USA). Current Molecular Medicine, 7(2), 185-197 (English) 2007 Bentham Science Publishers Ltd. CODEN: CMMUBP. ISSN: 1566-5240. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Similar to the human immunodeficiency virus (HIV), the hepatitis B virus (HBV) replicates via reverse transcription, in this case, within infected hepatocytes. Substantial advances have been achieved in the past ten years in developing and utilizing nucleoside/nucleotide analog drugs to inhibit HBV replication. Most are chain terminators that interfere with one or more steps in the replication cycle. Four of them (lamivudine, adefovir dipivoxil, entecavir, and telbivudine), have been approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B (CHB). In clin. trials of HBeAg pos. and neg. CHB patients, 48-52 wk of treatment with these drugs can induce a 4 - 7 log decrease of HBV viremia and histol. improvement. Long-term suppression of active HBV replication has been found to be assocd. with decreased inflammation, reversal of liver fibrosis and a lower incidence of hepatocellular carcinoma. However, permanent clearance of HBV is rarely achieved with current available antiviral agents, maintenance therapy being required for continuous suppression of HBV replication. In patients on continuous therapy, drug resistant mutations develop with all four drugs.In this experiment, several chemicals are used like 134678-17-4 and 163252-36-6 Combination therapy with different nucleos(t)ide analog drugs or nucleos(t)ide drugs and peglyated interferon needs further clin. study. Newer promising nucleotide analog drugs with more potent antiviral efficacy are also under development. .